| Record ID | marc_loc_updates/v36.i48.records.utf8:4913646:1332 |
| Source | Library of Congress |
| Download Link | /show-records/marc_loc_updates/v36.i48.records.utf8:4913646:1332?format=raw |
LEADER: 01332nam a22003138a 4500
001 2008049681
003 DLC
005 20081201163838.0
008 081113s2008 dcu b 000 0 eng
035 $a(DNLM)101489033
010 $a 2008049681
020 $a9780844742779
020 $a0844742775
040 $aDNLM/DLC$cDLC
042 $apcc
043 $an-us---
050 00 $aHD9666.6$b.V47 2008
060 10 $aQV 733.1$bV541p 2008
082 00 $a338.4/361510973$222
100 1 $aVernon, John A.
245 10 $aPharmaceutical price regulation :$bpublic perceptions, economic realities, and empirical evidence /$cJohn A. Vernon and Joseph H. Golec.
260 $aWashington, D.C. :$bAEI Press,$c2008.
263 $a0812
300 $ap. ;$ccm.
504 $aIncludes bibliographical references.
505 0 $aR&D investment in new drugs : how it works, and how it is harmed by price controls -- Government price regulation and the impact on pharmaceutical R&D spending -- Government intervention and the threats to drug R&D -- Summary and conclusions : why public policy must recognize the trade-off between lower prices today and life-saving medicines tomorrow.
650 0 $aPharmaceutical industry$xGovernment policy$zUnited States.
650 0 $aDrugs$xPrices$xLaw and legislation$zUnited States.
700 1 $aGolec, Joseph.